|
Monday, September 14, 2009
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
PCAsso Diagnostics
A research and development diagnostics company
About
|
PCAsso is developing PolyChromatic Angiography (PCA), the next generation angiography. PCA is a novel imaging technology that will provide quantitative analysis of leakage in the blood vessel of the retina. PCA is a disruptive technology that is expected to dominate the retinal angiography market. PCA technology is scalable and maybe adapted for use in any disease with vascular leakage and tap into the whole angiography market.
3 Major Issues
|
- What regulatory strategy should we use in the following :
A) Disease indication: diabetic retinopathy (7-8 million patients) or uveitis (200 thousands patients/orphan disease)
B) Label indication:
- Structure Delineation
- Disease or Pathology Detection or Assessment
- Functional, Physiological, or Biochemical Assessment
- Diagnostic or Therapeutic Patient Management
- What would be the best strategies for each of the following:
- Market preparation
- Market penetration
- Market domination
- What is the expected value of PCAsso at the following stages:
- IND/ pre-Phase I (proof of concept, Toxicology and CMC completed)
- Post Phase I (proven safety)
- Post Phase II (positive results)
- Post Phase III (positive results)
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
Slides
Audio
Video
Webcast
